HOME >> MEDICINE >> NEWS
Other highlights in the July 20 JNCI

Other highlights in the July 20 JNCI include a study identifying HPV types that may help manage cancer risk in women with cervical abnormalities, a study examining the risk of contralateral testicular cancer, a study that looks at the association between higher urinary melatonin levels and breast cancer risk, and a study examining how accurately Medicare claims data reflect chemotherapy use in elderly beneficiaries.

Identifying HPV Types May Help Manage Cancer Risk in Women With Cervical Abnormalities

Women whose Pap test results are equivocal or mildly abnormal and who are positive for human papillomavirus (HPV) type 16 have an increased risk of developing cervical precancer compared with women diagnosed with other HPV types, according to a new study. A second study concludes that distinguishing HPV type 16 and 18 during cervical cancer screening may identify women with normal cervical cytology at greatest risk of cervical precancer and permit less aggressive management of women with other types of HPV infections.

HPV type 16--the most common and oncogenic HPV type--and HPV18 account for 60% to 70% of cervical cancer cases worldwide. Other oncogenic types of HPV are responsible for virtually all remaining cases. A pooled test for 13 types of HPV is currently being used for triage of equivocal cervical cytology results in women of any age and as an adjunct screening test with cervical cytology for women ages 30 and older. However, it was not previously known whether detection of specific HPV types would be clinically helpful in management of cervical cancer risk in women.

To determine the risk of cervical precancer in women with HPV16, Philip E. Castle, Ph.D., M.P.H., of the National Cancer Institute, and colleagues tested 5,060 women enrolled in a study, the atypical squamous cells of undetermined significance (ASCUS) low-grade squamous intraepithelial lesions (LSIL) Triage Study (ALTS), for HPV16 and other oncogeni
'"/>

Contact: Sarah Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
19-Jul-2005


Page: 1 2 3 4 5

Related medicine news :

1. Other highlights in the May 2 JNCI
2. Other highlights in the Dec. 6 JNCI
3. Other illnesses play role in difference in breast cancer survival rates between blacks and whites
4. Other highlights in the October 5 JNCI
5. Other highlights in the May 18 JNCI
6. Other highlights in the May 4 JNCI
7. Research highlights from Thoracic Society Conference
8. SCAI highlights study using wireless technology to speed care of heart attack patients
9. SCAI Founders Lecture highlights remarkable progress in catheter-based aortic valve replacement
10. Latest IPCC report highlights need for integrated climate/human behavior models
11. New report highlights aromatase inhibitor side effects

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Other highlights the July JNCI

(Date:5/20/2013)... exposure to traffic-related air pollution was significantly associated ... to new research from the University of Cincinnati ... The research is detailed in a study being ... Perspectives , a peer-reviewed open access journal published ... an institute within the National Institutes of Health ...
(Date:5/20/2013)... 2013 For the third consecutive ... of Frederick Award in the Professional Standards Review ... , The USCA "Best of Local Business" Award ... Each year, the USCA identifies companies that they ... local community and business category. These are local ...
(Date:5/20/2013)... May 20, 2013 The new healthcare ... and health of all Americans. However, not all the ... impact as some might take up to 2014 to ... Services (HHS), some states are currently moving forward to ... Marketplaces, such as: Iowa, Michigan, New Hampshire, and West ...
(Date:5/20/2013)... Denver, Colorado (PRWEB) May 20, 2013 Daily ... willing to provide its readers with useful tips that can ... vitiligo. , According to the website Natural Vitiligo ... due to the numerous positive reviews it has received from ... a secret until now, but Daily Gossip has interviewed some ...
(Date:5/20/2013)... Australia (PRWEB) May 21, 2013 People are ... next. Stress levels are through the roof and are ... people handle this stress could mean the difference between life ... Change Begin’ event on 29 May will share valuable, practical ... wellbeing and influence the world around them for social good. ...
Breaking Medicine News(10 mins):Health News:Early-life traffic-related air pollution exposure linked to hyperactivity 2Health News:A2LA Receives 2013 Best of Frederick Award 2Health News:Review of Health Bill Impact in 2014 2Health News:Review of Health Bill Impact in 2014 3Health News:New Natural Vitiligo Treatment System That Helps People Treat Vitiligo Permanently Revealed by Daily Gossip Magazine 2Health News:Chill Out and Change the World, Say Mind Experts at V Star Bliss Event in Sydney 2
(Date:5/20/2013)... CARLSBAD, Calif. , May 20, 2013   ... today announced that its Applied Biosystems™ 3500 Dx and ... Federal Commission for Protection against Health Risks in ... marks a major extension of Life Technologies, capabilities to ... America with Sanger -based ...
(Date:5/20/2013)... May 20, 2013 Enrollment of patients with ... 2b dose-finding clinical trial of product candidate NewMet ... treatment for Type 2 diabetes. Elcelyx expects to complete ... in June. Results of the trial,s primary endpoint of ... summer, and the read-out for long-term glucose lowering and ...
(Date:5/20/2013)... , May 20, 2013  Medicare Part ... are overwhelmingly satisfied, citing lower costs, convenient access ... new survey from Hart Research Associates released today ... than 40% of Part D seniors (9.5 million) ... "Seniors like the lower costs, pharmacy ...
Breaking Medicine Technology:Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 2Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices 2
Cached News: